"We are excited to enter 2026, as we get closer to two potentially transformative readouts over the next 18 months for tibulizumab, starting with anticipated data from our TibuSHIELD study in patients with hidradenitis suppurativa in the fourth quarter of this year," said Kim Davis, interim CEO and COO at Zura. "We believe tibulizumab could be a paradigm shift in addressing the unmet needs of patients suffering from complex and debilitating immune disorders." "Tibulizumab is among the most advanced bispecific antibodies in development for autoimmune diseases and has the potential to break through the efficacy seen with single pathway inhibitors," said Kiran Nistala, Chief Medical Officer. "We have strengthened our clinical programs in order to generate high-quality, robust data that we believe will maximize our ability to showcase the clinical benefits of this unique molecule." For HS, the Phase 2 TibuSHIELD study continues to enroll well, with actual enrollment tracking ahead of initial projections. Given the faster-than-expected enrollment and to improve the study's power, Zura is expanding enrollment in the TibuSHIELD study to 225 participants (up from 180 participants previously). Zura is now anticipating topline data for TibuSHIELD in the fourth quarter of 2026. For SSc, enrollment is ongoing in the Phase 2 TibuSURE study. Based on the initial rate of enrollment observed in the study, Zura now expects to report topline data in the first half of 2027. Zura begins 2026 with cash and cash equivalents anticipated to be sufficient to support planned corporate and clinical operations through 2027, beyond the anticipated data readouts in both HS and SSc.
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 16.50 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 16.50 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.380
Low
15.00
Averages
16.50
High
18.00
Current: 6.380
Low
15.00
Averages
16.50
High
18.00
Clear Street
NULL
to
Buy
initiated
$18
2025-11-12
Reason
Clear Street
Price Target
$18
AI Analysis
2025-11-12
initiated
NULL
to
Buy
Reason
Clear Street initiated coverage of Zura Bio with a Buy rating and $18 price target. The firm said he rating reflects "strong conviction" in tibulizumab's ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.
H.C. Wainwright
H.C. Wainwright
Neutral
downgrade
$3 -> $2
2025-08-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $2
2025-08-19
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in potentially dilutive shares outstanding.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZURA
Unlock Now
Oppenheimer
Oppenheimer
Outperform
downgrade
$17 -> $16
2025-08-15
Reason
Oppenheimer
Oppenheimer
Price Target
$17 -> $16
2025-08-15
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $16 from $17 and keeps an Outperform rating on the shares after the company reported Q2 financial results and provided an update on their ongoing clinical studies of tibulizumab, with the global Phase 2 TibuSHIELD study in HS having launched in May. The firm's reported Q2 ending cash of $154.5M is anticipated to support operations through 2027 and readouts from both ongoing studies of tibulizumab.
Oppenheimer
Oppenheimer
Outperform
downgrade
$19 -> $17
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$19 -> $17
2025-05-09
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
